-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Establishment Labs (NASDAQ:ESTA) Stock Price Up 7.8%
Establishment Labs (NASDAQ:ESTA) Stock Price Up 7.8%
Establishment Labs Holdings Inc. (NASDAQ:ESTA – Get Rating) rose 7.8% during mid-day trading on Thursday . The company traded as high as $69.60 and last traded at $69.39. Approximately 3,896 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 110,256 shares. The stock had previously closed at $64.37.
Analysts Set New Price Targets
ESTA has been the topic of a number of recent analyst reports. Stephens dropped their price target on shares of Establishment Labs from $90.00 to $87.00 and set an "overweight" rating on the stock in a research report on Wednesday, December 28th. Mizuho assumed coverage on shares of Establishment Labs in a research report on Wednesday, October 12th. They set a "buy" rating and a $70.00 target price on the stock. Finally, BTIG Research boosted their target price on shares of Establishment Labs from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Friday, October 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Establishment Labs presently has an average rating of "Moderate Buy" and an average target price of $97.00.
Get Establishment Labs alerts:Establishment Labs Price Performance
The stock's 50 day simple moving average is $63.87 and its 200 day simple moving average is $60.34. The company has a debt-to-equity ratio of 97.56, a quick ratio of 3.29 and a current ratio of 4.27.
Establishment Labs (NASDAQ:ESTA – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.27). The business had revenue of $38.25 million for the quarter, compared to the consensus estimate of $37.55 million. Establishment Labs had a negative net margin of 49.50% and a negative return on equity of 209.77%. During the same quarter last year, the firm posted ($0.61) EPS. Analysts forecast that Establishment Labs Holdings Inc. will post -2.6 EPS for the current year.Institutional Trading of Establishment Labs
Hedge funds and other institutional investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA grew its stake in shares of Establishment Labs by 3,244.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 602 shares of the company's stock worth $41,000 after acquiring an additional 584 shares in the last quarter. Lazard Asset Management LLC grew its stake in shares of Establishment Labs by 104.5% in the 1st quarter. Lazard Asset Management LLC now owns 963 shares of the company's stock worth $64,000 after acquiring an additional 492 shares in the last quarter. BNP Paribas Arbitrage SNC grew its stake in shares of Establishment Labs by 100.6% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 1,689 shares of the company's stock worth $92,000 after acquiring an additional 847 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Establishment Labs by 38.4% in the 1st quarter. Bank of America Corp DE now owns 2,227 shares of the company's stock worth $150,000 after acquiring an additional 618 shares in the last quarter. Finally, Twin Lakes Capital Management LLC bought a new stake in shares of Establishment Labs in the 3rd quarter worth $163,000. Institutional investors own 75.26% of the company's stock.
About Establishment Labs
(Get Rating)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution.
See Also
- Get a free copy of the StockNews.com research report on Establishment Labs (ESTA)
- MarketBeat: Week in Review 01/09-01/13
- JPMorgan Chase Falls As Banks Brace For Recession
- Why is the Bed Bath & Beyond Stock Price up 261%?
- Roku Stock Price is Trending, Here's Why
- Carvana Stock Rally, Here's What You Need to Know
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.
成立实验室控股公司(纳斯达克代码:ESTA-GET评级)周四午盘上涨7.8%。该公司股价一度高达69.60美元,最新报69.39美元。午盘交易中,约有3,896股易手,较110,256股的日均成交量下降了96%。该股此前收盘价为64.37美元。
分析师设定新的价格目标
ESTA一直是最近许多分析师报告的主题。斯蒂芬斯在12月28日(星期三)的一份研究报告中将机构实验室的股票目标价从90.00美元下调至87.00美元,并对该股设定了“增持”评级。瑞穗在10月12日星期三的一份研究报告中对建立实验室的股票进行了报道。他们为该股设定了“买入”评级和70.00美元的目标价。最后,BTIG Research将其股票目标价从90美元上调至100.00美元,并在10月7日星期五的一份研究报告中给予该公司“买入”评级。一名投资分析师对该股的评级为持有,四名分析师对该股的评级为买入。根据MarketBeat.com的数据,机构实验室目前的平均评级为“中等买入”,平均目标价为97.00美元。
到达建立实验室警报:设施实验室性价比
该股的50日简单移动均线切入位为63.87美元,200日简单移动均线切入位为60.34美元。该公司的负债权益比率为97.56,速动比率为3.29,流动比率为4.27。
成立实验室(纳斯达克代码:ESTA-GET Rating)上一次公布季度收益是在11月7日星期一。该公司公布本季度每股收益(0.76美元),低于分析师普遍预期的(0.49美元)至(0.27美元)。该业务本季度的收入为3825万美元,而普遍预期为3755万美元。成立实验室的净利润率为负49.50%,净资产回报率为负209.77%。去年同期,该公司公布的每股收益为0.61美元。分析师预测,机构实验室控股公司本年度每股收益将达到2.6欧元。机构实验室的制度性交易
对冲基金和其他机构投资者最近买卖了该公司的股票。第一季度,法国巴黎银行套利公司在机构实验室的持股增加了3,244.4%。法国巴黎银行套利公司现在持有602股该公司股票,价值41,000美元,上个季度又购入了584股。Lazard Asset Management LLC在第一季度持有的机构实验室股份增加了104.5%。Lazard Asset Management LLC在上个季度增持了492股后,现在拥有963股该公司股票,价值6.4万美元。法国巴黎银行套利SNC在第三季度持有的机构实验室股份增加了100.6%。法国巴黎银行套利SNC现在拥有1,689股该公司股票,价值92,000美元,上个季度又收购了847股。今年第一季度,美国银行(Bank Of America Corp DE)在机构实验室的持股增加了38.4%。美国银行DE目前持有2,227股该公司股票,价值15万美元,此前该公司在上个季度增持了618股。最后,双湖资本管理有限责任公司在第三季度购买了价值16.3万美元的建立实验室新股。机构投资者持有该公司75.26%的股份。
关于机构实验室
(获取评级)
建立实验室控股公司是一家医疗技术公司,生产和营销用于美容和重建整形手术的医疗器械。该公司主要提供Motiva Implants品牌下的硅胶填充乳房植入物。它还提供Motiva Ergonomix和Motiva Ergonomix2重力敏感圆形软硅胶填充型乳房植入物;以及Motiva Flora组织扩张器,以及分销用于自体脂肪组织采集和再分配的纯移植物系列产品。
另请参阅
- 免费获取StockNews.com关于机构实验室的研究报告(ESTA)
- MarketBeat:回顾中的一周01/09-01/13
- 摩根大通破产,银行为衰退做好准备
- 为什么Bed Bath&Beyond的股价上涨了261%?
- Roku股价走势,原因如下
- Carvana Stock Rally,这是你需要知道的
接受机构实验室每日的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对机构实验室和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧